The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Some places in the world offer experiences so rare and surprising that they seem almost…
India is becoming a land of new ideas and bold dreams. Every day, young minds…
India is growing fast in science, technology, medicine, and innovation. New ideas, discoveries, and inventions…
India’s growth story continues to draw strong global attention. In the last six months, the…
Some countries are famous for their deep connection with animals. In one such country, a…
India has many beautiful national parks that protect animals, birds and nature. Some parks are…